Articles

Letters to the Editor

Published on 14 December 2017

Comment on the non-biological complex drugs paper

Abstract: Comment on the Special Report by Professor Gerrit Borchard: Complexity in the making: non-biological complex drugs (NBCDs) and the pharmacopoeias, published in GaBI Journal, 2016;5(1):36-41. Submitted: 3 November 2017; Revised: 13...

Author(s): Karthik Bodhinathan, PhD, MSM

Glatiramer acetate, multiple sclerosis, non-biological complex drug (NBCD)

DOI: 10.5639/gabij.2017.0604.032

5.400 views

Read more →

Commentary

Published on 14 December 2017

Global policies on pharmacy-mediated substitution of biosimilars: a summary

Abstract: An extensive overview of policies related to pharmacy-mediated substitution of biosimilars across the world was carried out by Larkin et al. in 2017. The details of this are discussed...

Author(s): Thijs J Giezen, PharmD, PhD, MSc

biosimilar, policy, regulation, substitution, switching

DOI: 10.5639/gabij.2017.0604.033

6.757 views

Read more →

Review Article

Published on 16 November 2017

Major lessons learned from Zarxio’s US launch: the start of a biosimilar revolution

Introduction: Launched in 2015, Zarxio™ (filgrastim-sndz) was the first biosimilar to gain US Food and Drug Administration (FDA) approval. In contrast, the first biosimilar was launched in Europe in 2006....

Author(s): Michael Sarshad, BSc, MBA

biosimilar, US Food and Drug Administration (FDA), Zarxio

DOI: 10.5639/gabij.2017.0604.035

23.341 views

Read more →

Meeting Report

Published on 13 November 2017

Perspectives on the future of pegfilgrastim biosimilars

Author byline as per print journal: Professor Pere Gascón, MD; Ruediger Jankowsky, PhD; Karsten Roth, PhD Abstract: Cinfa Biotech, the biosimilars specialists of the Cinfa Group, reviewed pegfilgrastim biosimilar approaches to...

Author(s): Karsten Roth, PhD, Professor Pere Gascón, MD, Ruediger Jankowsky, PhD

biosimilars, biotech, G-CSF, neutropenia, pegfilgrastim

DOI: 10.5639/gabij.2017.0604.040

12.908 views

Read more →

Special Report

Published on 13 November 2017

Building stakeholder confidence in biosimilar medicines through evidence-based information sharing

Abstract: The European Commission held a stakeholder event to discuss biosimilar medicinal products in May 2017. A session on building stakeholder confidence in biosimilar medicines provided an update of the...

Author(s): Assistant Professor Gianluca Trifirò, MD, PhD

best practice, biosimilar, interchangeability, pharmacovigilance, switching

DOI: 10.5639/gabij.2017.0604.038

5.348 views

Read more →

Research News

Published on 17 October 2017

HIV patients will accept generic treatments

Human immunodeficiency virus (HIV) patients in high-income countries are likely to accept the introduction of generic antiretroviral (ARV) drugs, according to a study carried out by researchers in Ireland [1]....

Author(s): GaBI Journal Editor

DOI: 10.5639/gabij.2017.0604.041

3.486 views

Read more →

Abstracted Scientific Content

Published on 17 October 2017

A comparison of European and US generic drug markets

Submitted: 19 June 2017; Revised: 5 September 2017; Accepted: 6 September 2017; Published online first: 19 September 2017 Introduction Comparative research on the European and US generic drug markets based...

Author(s): GaBI Journal Editor

DOI: 10.5639/gabij.2017.0604.043

32.708 views

Read more →

Perspective

Published on 17 October 2017

40th anniversary of essential medicines: a loud call for improving its access

Author byline as per print journal: Mohammad Bashaar, PhD; Professor Mohamed Azmi Hassali, PhD; Fahad Saleem, PhD Abstract: The soaring costs of medicine are a global dilemma. It was hoped that the...

Author(s): Fahad Saleem, Mohammad Bashaar, Professor Mohamed Azmi Hassali, PhD

access barriers, affordability, essential medicines, medicine prices

DOI: 10.5639/gabij.2017.0604.036

9.952 views

Read more →

Letters to the Editor

Published on 02 October 2017

Clear naming, traceability of biological medicines will protect patients

Author byline as per print journal: Adjunct Professor Valderilio Feijó Azevedo, MD, PhD, MBA; Associate Professor Brian Bressler, MD, MS, FRCPC; Madelaine A Feldman, MD, FACR; Professor Alejandro Mercedes, MD Abstract:...

Author(s): Alejandro Mercedes, MD, Associate Professor Valderilio Feijó Azevedo, MD, PhD, MSc, Brian Bressler, MD, Madelaine A Feldman, MD, FACR

Biological Qualifier (BQ), biosimilars, International Nonproprietary Name (INN), naming, pharmacovigilance, World Health Organization (WHO)

DOI: 10.5639/gabij.2017.0604.031

5.494 views

Read more →

Published on 27 September 2017

2017/3 GaBI Journal Table of Contents

Contents Editor’s Letter Latest features in GaBI Journal, 2017, Issue 3 Commentary Patent expiry and costs for anti­cancer medicines for clinical use Original Research A survey of Australian prescribers’ views...

2.558 views

Read more →

Editor's Letter

Published on 27 September 2017

Latest features in GaBI Journal, 2017, Issue 3

It is clear that greater use of generics and biosimilars could greatly decrease healthcare costs and thereby increase availability of important medicines. It is equally clear that these potential savings...

Author(s): Professor Philip D Walson, MD

DOI: 10.5639/gabij.2017.0603.020

3.262 views

Read more →

Research News

Published on 27 September 2017

Healthcare professionals will accept generic HIV treatments

Healthcare professionals working with HIV patients in high-income countries are likely to accept the introduction of generic antiretroviral drugs (ARVs), according to a study carried out by researchers in Ireland...

Author(s): GaBI Journal Editor

DOI: 10.5639/gabij.2017.0603.029

3.355 views

Read more →